HER2-negative metastatic breast cancer patients receiving first-line docetaxel: Survival data and prognostic factors

被引：0

作者：

Deblock, M. ^{[1
]}

Esterni, B. ^{[1
]}

Tarpin, C. ^{[1
]}

Charaffe-Jauffret, E. ^{[1
]}

Extra, J. M. ^{[1
]}

Viens, P. ^{[1
]}

Goncalves, A. ^{[1
]}

机构：

[1] Inst Paoli Calmettes, Marseille, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1105

引用

页数：1

共 50 条

[31] Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer [J].

Al Mahmasani, Layal ;

Amhaz, Ghid ;

Abou Zeidane, Reine ;

Chamseddine, Nathalie ;

Hatab, Taha ;

Sabbagh, Saad ;

Charafeddine, Maya ;

Assi, Hazem I. .

FRONTIERS IN ONCOLOGY, 2023, 13

[32] BevacizumabA Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer [J].

Katherine F. Croom ;

Sohita Dhillon .

Drugs, 2011, 71 :2213-2229

[33] Bevacizumab A Review of its Use in Combination with Paclitaxel or Capecitabine as First-Line Therapy for HER2-Negative Metastatic Breast Cancer [J].

Croom, Katherine F. ;

Dhillon, Sohita .

DRUGS, 2011, 71 (16) :2213-2229

[34] Biomarker study of patients with HER2-negative metastatic breast cancer receiving combination therapy with nivolumab, bevacizumab and paclitaxel as first-line treatment (WJOG9917BTR) [J].

Ozaki, Y. ;

Kitano, S. ;

Matsumoto, K. ;

Takahashi, M. ;

Mukohara, T. ;

Futamura, M. ;

Masuda, N. ;

Tsurutani, J. ;

Yoshimura, K. ;

Minami, H. ;

Takano, T. .

CANCER RESEARCH, 2019, 79 (04)

[35] Choice of primary endpoints in first-line phase III trials of HER2-negative or HER2-unknown metastatic breast cancer (MBC). [J].

Kuemmel, Sherko ;

Mueller, Volkmar ;

Lux, Michael P. ;

Weyer, Geerd ;

Pintoffl, Jan P. ;

Jackisch, Christian .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

[36] Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer [J].

Michael R. Clemens ;

Oleg A. Gladkov ;

Elaina Gartner ;

Vladimir Vladimirov ;

John Crown ;

Joyce Steinberg ;

Fei Jie ;

Anne Keating .

Breast Cancer Research and Treatment, 2015, 149 :171-179

[37] Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study [J].

Manso, Luis ;

Garcia Palomo, Andres ;

Perez Carrion, Ramon ;

Cassinello, Javier ;

Gallegos Sancho, Isabel ;

Chacon Lopez-Muniz, Ignacio ;

Olier, Clara ;

Fernandez-Aramburo, Antonio ;

Llorca, Cristina ;

Gonzalez, Xavier ;

Llorente, Rosa ;

Torregrosa, Dolores ;

Alvarez, Inaki ;

Galve, Elena ;

Bueno, Coralia ;

Garau, Isabel ;

Garcia, Maria Jose ;

Gonzalez-Santiago, Santiago ;

Ballesteros, Ana Isabel ;

Blanco, Esperanza ;

Galan, Antonio ;

Gonzalez, Sonia ;

Perello, Antonia ;

Cortes-Funes, Hernan ;

Gravalos, Cristina .

ANTICANCER RESEARCH, 2015, 35 (12) :6941-6950

[38] A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer [J].

Tryfonidis, K. ;

Boukovinas, I. ;

Xenidis, N. ;

Christophyllakis, C. ;

Papakotoulas, P. ;

Politaki, E. ;

Malamos, N. ;

Polyzos, A. ;

Kakolyris, S. ;

Georgoulias, V. ;

Mavroudis, D. .

BREAST, 2013, 22 (06) :1171-1177

[39] Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer [J].

Clemens, Michael R. ;

Gladkov, Oleg A. ;

Gartner, Elaina ;

Vladimirov, Vladimir ;

Crown, John ;

Steinberg, Joyce ;

Jie, Fei ;

Keating, Anne .

BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) :171-179

[40] Prognostic Factors for Long-Term Eribulin Response in a Cohort of Patients With HER2-Negative Metastatic Breast Cancer [J].

El Kaddissi, Antoine ;

Vernerey, Dewi ;

Falcoz, Antoine ;

Mansi, Laura ;

Bazan, Fernando ;

Chaigneau, Loic ;

Dobi, Erion ;

Goujon, Morgan ;

Meneveau, Nathalie ;

Paillard, Marie-Justine ;

Selmani, Zohair ;

Viot, Julien ;

Molimard, Chloe ;

Monnien, Franck ;

Woronoff, Anne-Sophie ;

Curtit, Elsa ;

Borg, Christophe ;

Meynard, Guillaume .

CLINICAL BREAST CANCER, 2024, 24 (07) :e622-e632.e5

← 1 2 3 4 5 →